Navigation Links
Six Presentations on Tocagen's Toca 511 to be Given at the Society of Neuro-Oncology Annual Meeting
Date:11/22/2013

SAN DIEGO, Nov. 22, 2013 /PRNewswire/ -- Tocagen Inc. today announced that six presentations on Toca 511 will be given at the Society of Neuro-Oncology (SNO) Annual Meeting, including interim clinical data from two ongoing Phase I investigational studies, which show that, to date, Toca 511 administration followed by oral courses of Toca FC is safe and well tolerated, and demonstrated antitumor activity in some patients with high grade glioma (HGG). HGG includes glioblastoma multiforme (GBM), the most common and aggressive form of primary brain cancer. Toca 511 is a retroviral replicating vector that carries a gene for an enzyme that converts orally delivered Toca FC (extended-release 5-FC) into 5-FU, a potent anti-cancer agent.

The data will be presented at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 18th Annual Meeting of the Society for Neuro-Oncology in San Francisco. Timothy Cloughesy, M.D., director of the Neuro-Oncology Program at the University California, Los Angeles Jonsson Cancer Center and a principal investigator for the Toca 511 resection study, will make an oral presentation titled "Evidence supporting mechanism of action and drug activity in Phase I trial of patients with recurrent high grade glioma administered Toca 511 at the time of surgical resection followed by Toca FC." This presentation will be given on Sunday, Nov. 24, during the Biologic/Immunologic Therapies session from 10:20 a.m. to 12 p.m. PST.

Data from additional studies of Toca 511 will be presented at the conference in the following poster presentations:

  • "A phase I trial of a retroviral replicating vector (Toca 511) in patients with recurrent high grade glioma demonstrates importance of real-time MRI-guided delivery for evaluation of safety and efficacy,"  Friday Nov. 22, 7 to 9 p.m. PST
  • "Intravenous administration of Toca 511 results in uniform distribution of viral spread within the tumor and increased survival in a synergistic, orthotopic mouse glioma model," Saturday Nov. 23, 5 to 7 p.m. PST
  • "Toca 511 gene transfer in combination with temozolomide appears safe and demonstrates synergistic therapeutic efficacy in mouse glioblastoma model," Saturday Nov. 23, 5 to 7 p.m. PST
  • "Prodrug activator gene therapy with a non-lytic retroviral replicating vector (Toca 511) radiosensitizes glioma cells after intracellular generation of 5-fluorouracil," Saturday, Nov. 23, 5 to 7 p.m. PST
  • "Enhancing retroviral replicating vector-mediated prodrug activator gene therapy with engineered mesenchymal stem cells in animal models of glioma," Saturday Nov. 23, 5 to 7 p.m. PST

About Toca 511 & Toca FC

The combination of Toca 511 (vocimagene amiretrorepvec) for injection and Toca FC (flucytosine) extended-release tablets, is being investigated in Phase I studies at leading centers across the US in clinical studies in patients with recurrent high grade glioma, including GBM. Toca 511 is a retroviral replicating vector (RRV) that is designed to deliver a prodrug activator gene called cytosine deaminase (CD) selectively to cancer cells. After allowing time for Toca 511 to spread through the tumor, those cancer cells expressing the CD gene can convert the antibiotic drug flucytosine into the anti-cancer drug 5-fluorouracil (5-FU). By producing 5-FU locally, this technology has the potential to produce much higher intratumoral concentrations of 5-FU than can be attained with systemic administration.  In these studies, patients receive a single administration of Toca 511 at the time of surgery (craniotomy or transcranial) followed by repeat cycles of oral Toca FC. To date, a total of 57 patients have received the combination therapy in the two studies.

About Tocagen

Tocagen Inc. is a privately funded, clinical stage biopharmaceutical company pursuing the discovery, development and commercialization of gene therapy products for the treatment of cancer. Tocagen is initially focusing on treatments for patients with advanced cancer for whom no adequate treatments currently exist. Toca 511 & Toca FC, the company's lead investigational combination product candidate, is being evaluated in two clinical trials in patients with recurrent high grade glioma, including GBM. Tocagen has received grant support from leading brain cancer foundations including, Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation, and Voices Against Brain Cancer (VABC). For more information about Tocagen or Toca 511 please visit www.tocagen.com or www.clinicaltrials.gov.


'/>"/>
SOURCE Tocagen Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cyberonics To Webcast Presentations From Companys Investor And Analyst Meeting
2. Star Scientific Files Third-Quarter Financials for 2013; Comments on Companys Corporate Leadership Transition, Roskamp Institute Scientific Presentations at 2013 Annual Society for Neuroscience Convention
3. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
4. ViroPharma Announces Upcoming Data Presentations at the 2013 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting
5. Thoratec Announces Presentations At Investor Conferences For November 2013
6. Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013
7. Volcano Announces Upcoming Data Presentations from Large-Scale Studies on Physiology and Imaging Technologies at TCT 2013
8. Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting
9. Diabetes Alliance to Feature 17 Presentations for Linagliptin and Investigational Compound Empagliflozin^ During the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD)
10. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
11. CTI Announces Data Presentations at the 18th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... Switzerland , April 27, 2016 ... AG announced the launch of a Phase 2 clinical ... residual hearing in patients undergoing cochlear implantation (CI) surgery. ... recruiting patients in Germany and ... into the middle ear at the time of surgery. ...
(Date:4/26/2016)... 26, 2016 Hill-Rom Holdings, Inc. (NYSE: ... at the Deutsche Bank 41 st Annual Health Care ... You are invited to listen to the live ... access it directly at http://edge.media-server.com/m/p/mr4uxgas . A recorded replay ... of the live event and accessible at the links above ...
(Date:4/26/2016)... , April 27, 2016 Research ... "Global Molecular Diagnostics Market 2016-2020" report to their ... , ,The global molecular diagnostics market is projected to ... 2016-2020. Molecular diagnostics is a technique that ... the molecular level to detect changes in biochemical pathways. ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... The ... , a program to critically evaluate and rank health-focused applications and connected devices ... to provide independent, unbiased and accurate information to help accelerate patient and provider ...
(Date:4/30/2016)... (PRWEB) , ... April 30, 2016 , ... Orlando-based Maximized ... as they go for gold in Rio. Under the care of Maximized Living ... golds! , In an unprecedented showing, Maximized Living is sending the largest contingent of ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... notified by the Accreditation Council for Graduate Medical Education (ACGME) that it has ... This is the first accreditation of three residency programs that Memorial is currently ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... ... advocating optimistic healthcare awareness and author of best seller "LOVE, MEDICINE and MIRACLES") ... Radio Monday, May 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, ...
(Date:4/29/2016)... ... 2016 , ... Spine Team Texas, a comprehensive spine physician group specializing in ... physicians has been invited to be a featured speaker at the Texas Society of ... April 30, 2016. , Dr. R. Scott McPherson, a physical medicine and rehabilitation ...
Breaking Medicine News(10 mins):